Streetbeat News

Stock Prices

ABBV

AbbVie Inc (NYSE:ABBV) reported positive Phase 2 trial results for Teliso-V in treating a subtype of advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC) patients. The study showed an overall response rate of 35% in c-Met High and 23% in c-Met Intermediate patients, with median overall survival of 14.6 and 14.2 months, respectively. The safety profile was consistent with previous findings, and no new safety concerns were identified. AbbVie's stock rose 0.60% to $138.91.

Portfolio Pulse from Vandana Singh

November 29, 2023 | 6:21 pm

AAPL

FNDA

GOOGL

MSFT

NVDA

SPY

Analysts predict an 11% return for the S&P 500 index in 2024, buoyed by lower interest rates and a soft landing for the economy. The SPDR S&P 500 ETF Trust (SPY) has mirrored the index's performance, with an 18-19% increase in 2023. DataTrek suggests the Russell 3,000 index for those seeking more exposure to lower rates, highlighting the Schwab Fundamental U.S. Small Company Index ETF (FNDA) as an option. Despite large moves in big tech stocks, DataTrek sees potential for further gains in 2024, especially for Nvidia (NVDA), Alphabet (GOOGL), Apple (AAPL), and Microsoft (MSFT), which could significantly contribute to the S&P 500's performance due to their substantial market cap weight.

Portfolio Pulse from Neil Dennis

November 29, 2023 | 6:19 pm

INCY

Truist Securities analyst Srikripa Devarakonda has reiterated a Buy rating on Incyte (NASDAQ:INCY) and maintained a $91 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 6:13 pm

NTAP

NetApp, Inc. (NASDAQ:NTAP) stock is rising after reporting Q2 earnings of $1.58 per share and sales of $1.56 billion, surpassing estimates. The company also provided Q3 guidance above expectations. Analysts from Barclays, Wells Fargo, Raymond James, Stifel, Wedbush, and Morgan Stanley have updated their price targets for NetApp, all increasing their previous targets.

Portfolio Pulse from Erica Kollmann

November 29, 2023 | 6:12 pm

AULT

Ault Alliance's stock is trading higher following the company's announcement of its plans to initiate an exchange offer. The offer aims to acquire shares of its common stock in exchange for up to $15 million in Series D preferred shares.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 6:05 pm

CVS

ELV

HUM

UNH

Cigna Group (NYSE:CI) and Humana Inc (NYSE:HUM) are in talks about a potential merger, which could be a significant event in the health insurance industry. The deal, which may include both stock and cash, is expected to be completed by year-end. This merger would create a new competitor to UnitedHealth Group Inc (NYSE:UNH) and CVS Health Inc (NYSE:CVS), combining Cigna's pharmacy-benefit unit and commercial insurance with Humana's Medicare business. Previous merger attempts by Cigna with other companies faced antitrust issues. Humana's CEO transition plan is underway, with Jim Rechtin set to become President and COO, and eventually CEO. Cigna's stock fell 5.6%, while Humana's dropped 1.17%.

Portfolio Pulse from Vandana Singh

November 29, 2023 | 6:02 pm

WTER

The Alkaline Water Company's stock is trading lower following the receipt of a deficiency letter from Nasdaq due to the late filing of its Form 10-Q.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 6:00 pm

JYD

Jayud Global Logistics' stock is trading higher following the announcement of a strategic partnership with Shandong Oranda Logistics.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 5:58 pm

PBLA

Panbela Therapeutics' stock is trading higher following a recommendation from the independent Data Safety Monitoring Board to continue its study without modification.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 5:56 pm

AMC

CNK

IMAX

AMC Entertainment Holdings is set to release 'Renaissance: A Film by Beyonce,' expected to gross $40 million worldwide in its opening, following the success of Taylor Swift's concert film. The film will be shown in premium formats, including IMAX theaters, and will also be available at Cinemark Holdings locations. These releases, part of AMC's Q4 earnings, could significantly impact the company's financial results, especially with the Swift film grossing $250 million. AMC's stock is up 5.22% but down 80% YTD.

Portfolio Pulse from Chris Katje

November 29, 2023 | 5:54 pm